Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2088-2099

  Ivanov, Andrei A ^a   Wang, Ben ^a   Klutz, Athena M ^a   Chen, Vincent L ^a   Gao, Zhan Guo ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3'' (6'' BROMO 1'' (4 TOLUENESULFONYL)INDOLYL)ETHYLOXY) 6 (4 ((PHENYLCARBAMOYL)METHOXY)PHENYLAMINO) 3',4',5' TRIACETYLADENOSINE; 2 (3'' (6'' BROMO 1'' N INDOLYL)ETHYLOXY 6 (4 ((PHENYLCARBAMOYL)METHOXY)PHENYLAMINO)ADENOSINE; 2 (3'' (6'' BROMO 1'' N INDOLYL)ETHYLOXY) 6 (4 ((N PYRROLIDINECARBAMOYL)METHOXY)PHENYLAMINO)ADENOSINE; 2 (3'' (6'' BROMOINDOLYL)ETHYLOXY) 6 (N FURAN 2 CARBONYL)HYDRAZINOADENOSINE; 2 (3'' (6'' BROMOINDOLYL)ETHYLOXY) 6 HYDRAZINOADENOSINE; 2 3'' (6'' BROMO 1'' N INDOLYL)ETHYLOXY) 6 (4 CARBOXYLMETHOXY)PHENYLAMINO) 3',4',5' TRIACETYLADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2B RECEPTOR; ADENOSINE DERIVATIVE; ADENYLATE CYCLASE; AMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATOM; BIOLOGY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONFORMATION; DRUG SCREENING; DRUG SYNTHESIS; EMBRYO; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MODEL; NONHUMAN; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL PARAMETERS;

ADENOSINE; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; ELECTROSTATICS; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, ADENOSINE A2B; STEREOISOMERISM;

EID: 41849089695     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701442d     Document Type: Article

References (53)

1. Jacobson, K. A.; Gao, Z.-G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug. Discovery 2006, 5, 247-264.
2. Burnstock, G. Purine and pyrimidine receptors. Cell. Mol. Life Sci. 2007, 64, 1471-1483.
3. Gao, Z.-G.; Jacobson, K. A. Emerging adenosine receptor agonists. Expert Opin. Emerging Drugs 2007, 12, 479-492.
4. 2B adenosine receptors. Circulation 2007, 115, 1581-1590.
5. Németh, Z. H.; Bleich, D.; Csóka, B.; Pacher, P.; Mabley, J. G.; Himer, L.; Vizi, E. S.; Deitch, E. A.; Szabó, C.; Cronstein, B. N.; Haskó, G. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 2007, 10, 2379-2388.
6. Sum, C. S.; Tikhonova, I. G.; Neumann, S.; Engel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Identification of residues important for agonist recognition and activation in GPR40. J. Biol. Chem. 2007, 282, 29248-29255.
7. Ivanov, A. A.; Voronkov, A. E.; Baskin, I. I.; Palyulin, V. A.; Zefirov, N. S. The study of the mechanism of binding of human ML1A melatonin receptor ligands using molecular modeling. Dokl. Biochem. Biophys. 2004, 394, 49-52.
8. Li, J. H.; Han, S.-J.; Hamdan, F. F.; Kim, S.-K.; Jacobson, K. A.; Bloodworth, L. M.; Zhang, X.; Wess, J. Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands. J. Biol. Chem. 2007, 282, 26284-26293.
9. Rodina, E. V.; Vorobyeva, N. N.; Kurilova, S. A.; Belenikin, M. S.; Fedorova, N. V.; Nazarova, T. I. ATP as effector of inorganic pyrophosphatase of Escherichia coli. Identification of the binding site for ATP. Biochemistry (Moscow) 2007, 72, 93-99.
10. 2B receptor antagonists. J. Med. Chem. 2005, 48, 6813-6820.
11. 2B receptor. Minerva Biotecnol. 2005, 16, 79-83.
12. 3 adenosine receptor. J. Mol. Graphics Modell. 2006, 25, 562-577.
13. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. J. Med. Chem. 2007, 50, 4061-4074.
14. 1adenosine receptor reengineered for orthogonal recognition by tailored nucleosides. Biochemistry 2007, 46, 7437-7448.
15. Ivanov, A. A.; Palyulin, V. A.; Zefirov, N. S. Computer aided comparative analysis of the binding modes of the adenosine receptor agonists for all known subtypes of adenosine receptors. J. Mol. Graphics Modell. 2007, 25, 740-754.
16. 2B adenosine receptor. J. Med. Chem. 2007, 50, 1810-1827.
17. Loging, W.; Harland, L.; Williams-Jones, B. High-throughput electronic biology: mining information for drug discovery. Nature Rev. Drug Discovery 2007, 6, 220-230.
18. Muegge, I.; Oloff, S. Advances in virtual screening. Drug Discovery Today 2006, 3, 405-411.
19. Akamatsu, M. Current state and perspectives of 3D-QSAR. Curr. Top. Med. Chem. 2002, 2, 1381-1394.
20. 6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg. Med. Chem. 2004, 12, 2021-2034.
21. 3 adenosine receptor antagonists. J. Med. Chem. 1998, 41, 3186-3201.
22. 3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study. J. Med. Chem. 2005, 48, 152-162.
23. 2A adenosine receptor agonists. J. Med. Chem. 2001, 44, 531-539.
24. 1 adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies. Org. Biomol. Chem. 2005, 3, 2262-2270.
25. 2B adenosine receptor agonists. J. Med. Chem. 2007, 50, 374-380.
26. 2B adenosine receptor. Bioorg. Med. Chem. 2007, 15, 2514-2527.
27. Dooley, M. J.; Quinn, R. J. The three binding domain model of adenosine receptors: molecular modeling aspects. J. Med. Chem. 1992, 35, 211-216.
28. 3 receptor agonists. J. Med. Chem. 2004, 47, 4766-4773.
29. Okada, T.; Sugihara, M.; Bondar, A.-N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of new 2.2 Å crystal structure. J. Mol. Biol. 2004, 342, 571-583.
30. Lodowski, D. T.; Salom, D.; Le Trong, I.; Teller, D. C.; Ballesteros, J. A.; Palczewski, K.; Stenkamp, R. E. Crystal packing analysis of rhodopsin crystals. J. Struct. Biol. 2007, 158, 455-462.
31. Schueler-Furman, O.; Wang, C.; Bradley, P.; Misura, K.; Baker, D. Progress in modeling of protein structures and interactions. Science 2005, 310, 638-642.
32. Fanelli, F.; De Benedetti, P. G. Computational modeling approaches to structure-function analysis of G protein-coupled receptors. Chem. Rev. 2005, 105, 3297-3351.
33. Mohamadi, F. N.; Richards, G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macro-Models an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
34. Costanzi, S.; Ivanov, A. A.; Tikhonova, I. G.; Jacobson, K. A. Structure and function of G protein-coupled receptors studied using sequence analysis molecular modeling and receptor engineering: adenosine receptors. Front. Drug Des. Discovery 2007, 3, 63-79.
35. Ivanova, A. A.; Ivanov, A. A.; Oliferenko, A. A.; Palyulin, V. A.; Zefirov, N. S. Highly diverse, massive organic data as explored by a composite QSPR strategy: an advanced study of boiling point. SAR QSAR Environ. Res. 2005, 16, 231-246.
36. 3 adenosine receptor: analysis of binding and relative efficacy. J. Chem. Inf. Model. 2007, 47, 1225-1233.
37. Moro, S.; Bacilieri, M.; Ferrari, C.; Spalluto, G. Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as alternative attractive tool to generate ligand-based 3D QSARs. Curr. Drug Discovery Technol. 2005, 2, 13-21.
38. 3 adenosine receptor antagonists. J. Med. Chem. 1999, 42, 706-721.
39. Palyulin, V. A.; Radchenko, V. A.; Zefirov, N. S. Molecular field topology analysis method in QSAR studies of organic compounds. J. Chem. Inf. Comput. Sci. 2000, 40, 659-667.
40. 1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. J. Med. Chem. 2007, 50, 3229-3241.
41. 2A receptor ligands. Bioorg. Med. Chem. 2007, 15, 6956-6974.
42. Tikhonova, I. G.; Baskin, I. I.; Palyulin, V. A.; Zefirov, N. S. CoMFA and homology-based models of the glycine binding site of N-methyl-D-aspartate receptor. J. Med. Chem. 2003, 46, 1609-1616.
43. SYBYL, version 7.3; Tripos Inc. (1699 South Hanley Road, St. Louis, MO 63144).
44. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
45. San Juan, A. A. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein. J. Mol. Graphics Modell. 2007, 26, 482-493.
46. de Zwart, M.; Link, R.; von Frijtag Drabbe Künzel, J. K.; Cristalli, G.; Jacobson, K. A.; Townsend-Nicholson, A.; IJzerman, A. P. Nucleosides Nucleotides 1998, 17, 969-985.
47. 2B adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyl adenosine and NECA derivatives. Nucleosides, Nucleotides Nucleic Acids 2004, 23, 471-481.
48. 2B ligands. J. Med. Chem. 2002, 45, 3271-3279.
49. Ballesteros, J.; Weinstein, H. Integrated methods for the construction of three-dimensional models of structure-function relations in G protein-coupled receptors. Methods Neurosci. 1995, 25, 366-428.
50. 3 adenosine receptor antagonists. J. Med. Chem. 2005, 48, 4910-4918.
51. Gao, Z. G.; Mamedova, L. M.; Chen, P.; Jacobson, K. A. 2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. Biochem. Pharmacol. 2004, 68, 1985-1993.
52. Molecular Operating Environment, version 2008.05; Chemical Computing Group: Montreal, Canada.
53. 2 adrenergic receptor function. Science 2007, 318, 1266-1273.